Patient 1. A 32-year-old man, undergoing hemodialysis for approximately seven months because of end-stage renal disease due to focal glomeruloscierosis, developed an asymptomatic increase in serum ALT (160 lU/liter) and AST (230 lU/liter) levels (upper limit of normal for ALT and AST, 40 lU/liter). The HBsAg and other hepatitis B virus (HBV) serologic markers were negative. Because the ALT and AST remained elevated for longer than six months, liver biopsy was performed seven years ago. Histologic examination revealed lobular activity without fibrosis and thus mild chronic hepatitis. interpreted according to the most recently adopted criteria for grading (intensity of necroinfiammatory activity) and staging (fibrosis) of chronic hepatitis [11, the histologic findings were classified as grade 8 and stage 0 (maximum score for grading and staging, 18 and 6 respectively). The histologic picture was compatible with that of non-A, non-B hepatitis. This diagnosis was confirmed later, when antibody against hepatitis C virus (anti-HCV) was detected in a stored serum sample.
lU/liter (upper limit of normal, 306 IU/hter), and HCV RNA was detectable in the serum. Liver uitrasonography showed no evidence of extrahepatic cholestasis. A liver biopsy revealed moderate chronic hepatitis characterized mainly by lobular activity (grade 9); fibrosis was minimal (stage 1). Two years ago, the liver biochemistry was unchanged, but the HCV RNA was still positive, and the serum bDNA was 1.75 HCV Eq/mi X iO. A second liver biopsy was performed. Compared to the previous one, this biopsy showed that although the degree of activity had decreased slightly (grade 8), fibrosis was now prominent (stage 4). Four months ago (slightly longer than 5.5 years after transplantation and 1.5 years after the second liver biopsy), the patient presented with ascites and gross edema of the legs. Serum ALT, AST, yGGT, and alkaline phosphatase were 74 IU/hter, 50 lU/liter, 304 lU/liter, and 450 lU/liter, respectively; serum biliruhin was 1.2 mg/dl, and total plasma proteins were 5.3 g/dl (albumin, 2.6 g/di; globulin, 1.1 g/di). Serum bDNA was 3.5 HCV Eq/mi >< iO. Color Doppler ultrasonography of the liver showed minimal dilation of the portal vein without signs of collateral circulation. Following a diuretic-induced remission of the ascites, a third liver biopsy revealed a further reduction in necroinfiammatory activity (grade 7), a further increase in fibrosis (stage 6), and early signs of cirrhosis. Recent determination of the HCV genotype showed that the patient was infected with genotype lb. liver disease, whereas in the second, aggressive liver disease led to cirrhosis.
The development and refinement of molecular biology techniques ended our previous ignorance regarding the causative agent of non-A, non-B hepatitis (NANBH) and lcd to the identification of HCV as its primary cause. Hepatitis C virus was cloned in 1989 from complementary DNA (cDNA) extracted from the plasma of chimpanzees with infectious NANBH [2] . Subsequently, HCV was established as the causative factor in most cases of NANBH (80% to 90%) [3, 4] . Over the next few years, intensive research led to the characterization of the entire HCV genome, recognition of its genetic variability, development of tests for antibody as well as qualitative and quantitative detection of the viral genome, and knowledge about the epidemiology, natural history, and treatment of HCV infection.
Hepatitis C virus infection has become a common part of everyday clinical nephrology. Apart from occurring frequently among dialysis and renal transplant patients, HCV infection often is accompanied by cryoglobulinemia and some forms of immunologically mediated renal disease. In this Forum I will highlight, from a clinical point of view, our current state of knowledge regarding HCV infection in renal transplant recipients.
Molecular biology of HCV
Hepatitis C virus has been identified and characterized exclusively by means of molecular biology techniques. It is a small, lipoid-enveloped, single-stranded, positive-sense RNA virus assigned to the family of flaviviridae [5] . Its genome consists of about 9500 nucleotides [2] containing a single, large translational open-reading frame (ORF) (Fig. 1) . Preceding the 5' end and following the 3' end of the ORF, a number of nucleotides are present, comprising the untranslated (UT) regions of the genome [6, 71. The UT region at the 5' end is highly conserved and contributes to the translation of the viral genome [8] . The ORF encodes a large polyprotein precursor of about 3010 aminoacids that is post-translationally cleaved to produce the structural and nonstructural polypeptides of the virus [6] [7] [8] [9] [10] . The structural regions at the amino-terminal end of the genome encode the core (C) protein (p22) and the two envelope glycoproteins El (gp35) and E2/NSI (gp72). These regions are followed by four regions (NS2-NS5) that code for the nonstructural proteins. The function of the nonstructural proteins has not yet been fully elucidated, but it seems that they take part in virus replication and code for proteases (NS2, N53), helicase (NS3), and RNA-dcpendent RNA polymerase (NS5) [9, 10] . The HCV genome exhibits considerable nucleotide sequence heterogeneity, which is not evenly distributed. The 5' terminal UT region is the most highly conserved (92% nucleotide homology), the C and NS3 regions are relatively well conserved (81% and 70% nucleotide homology), and the other regions are less conserved (26% to 66% nucleotide homology) [10] . The extreme amino terminal end of the E2 envelope glycoprotein exhibits extensive hypervariability (hypervariable region) [10, 11] . Frequent mutations in this region explain, at least partially, why in HCV infection immune response is usually ineffective and why production of antibodies against HCV is not followed by clearance of the virus and immunity (immune escape) [10] .
The nuelcotide sequence heterogeneity of the genome led to the recognition of different HCV genotypes. The different classifications and nomenclatures assigned to the genotypes have caused considerable confusion. Hopefully, a recent consensus nomenclature, based on a sequence analysis of the NS5 region proposed by Simmonds and 45 other researchers worldwide [12] , will end the confusion. According to this newer classification, a sequence similarity of less than 72% with any known sequence is considered evidence for the existence of a new HCV type, whereas a maximum sequence similarity of 75% to 86% is considered evidence for a new subtype. The known types are numbered starting from 1, and the subtypes are classified as a,b,c.. . in order of discovery.
Diagnostic tests for HCV infection
The detection of anti-HCV antibodies and viral nucleic acid in the serum are currently the only means by which HCV infection can be diagnosed. The first test used for detecting anti-HCV was the so-called "first-generation" enzyme-linked immunosorbent assay (ELISA-1) [13] . This assay detects antibodies to the recombinant antigen C100 that is part of the NS4 region of the HCV genome. The low sensitivity and specificity of this test [3] brought -clOO about the development of the more sensitive and specific secondgeneration ELISA (ELISA-2) test, which detects antibodies to two additional recombinant proteins derived from the capsid (C22) and the NS3 region (C33c) of the HCV genome [141. The third-generation ELISA test (ELISA-3), which includes an additional antigen from the NS5 region, is even more sensitive [15, 161 (Fig. 2) . Moreover, a supplementary assay, the second-generation recombinant immunoblot assay (RIBA-2), which detects antibodies to the 5-1-1, C100, C33, and C22 proteins, is used to confirm positive anti-HCV ELISA tests [171. The RIBA-3 test detects an additional antibody (to the recombinant NS5 antigen) [10] . The absence of a direct assay for antigenemia makes detecting the HCV genome necessary for ascertaining the presence of viremia. However, since viral titers in HCV infection are too low to be directly detected by conventional nucleic acid hybridization techniques, the viral nucleic acid must be amplified. Detection is accomplished by reverse transcription (RT) of the hepatitis C virus RNA to cDNA and its amplification through polymerase chain reaction (PCR) [18] [19] [20] . The 5' UT highly conserved region of the HCV genome is the target of current PCR techniques. As RT-PCR can detect viremia shortly after acquisition of HCV infection and prior to the appearance of anti-HCV [211, RT-PCR is the only definitive test for diagnosing HCV infection. The polymerase chain reaction technique is very sensitive and specific, provided that strict measures for the avoidance of contamination (false-positive results) and storage (false-negative results) of the blood samples are applied [22] . Quantitative assessment of serum hepatitis C virus RNA load is obtained with the branched-chain DNA (bDNA) assay, in which synthetic DNA molecules are used, and the signal probe (instead of the viral nucleic acid) is amplified [23] [24] [25] . The specific hybridization of synthetic oligonucleotides to the 5' UT region and the core genes of the hepatitis C virus RNA allows for the RNA to be captured onto the surface of a well. Synthetic bDNA molecules and multiple copies of an alkaline-phosphatase-linked probe are hybridized to the immobilized complex (signal amplification). Detection is achieved by incubating the complex with a chemiluminescent substrate and by measuring the light emission generated by the bound alkaline phosphatase. Light emissions are proportional to the amount of hepatitis C virus RNA present in the sample. Hepatitis C virus RNA is quantified by comparing the light emission of the test sample to that of a standard curve defined by light emissions from known quantities of hepatitis C virus RNA. Although the branched-chain DNA assay is much less sensitive than is PCR (the lower limit of detection is 350,000 and 2,000 copies of HCV RNAJm1 for bDNA and PCR, respectively), the bDNA assay is less laborious and less time consuming, and it exeludes false-positive results due to contamination [23] .
HCV infection in dialysis patients
Although this Forum focuses on the problem of HCV infection in renal transplant recipients, a brief digression to HCV infection in dialysis patients is useful because these patients constitute the pool of candidates for renal transplantation. Further, most renal transplant recipients acquire HCV infection while they are on dialysis.
The prevalence of anti-HCV-positive hemodialysis patients varies considerably among countries. An assessment by the European Renal Association (ERA)-European Dialysis and Transplant Association (EDTA), using information taken from the 1993 center questionnaire of patients undergoing hemodialysis in all European and Mediterranean countries, showed that 17.7% were anti-HCV positive [26] . In the majority of the countries bordering the Mediterranean sea, the prevalence ranges between 20% and 30% (Portugal, 29%; Spain, 25%; France, 19%; Italy, 27%; Greece, 24%; Turkey, 30%). Exceptions are Egypt (44%), Israel, (14%), and Lebanon (5%). In some Eastern European countries, the percentage of anti-HCV-positive patients is very high as well (Poland, 29%; Romania, 35%). Other European countries have lower prevalences (UK, 2%; Sweden, 8%; Germany, 7.5%; Austria, 10%). In 1994, the incidence of anti-HCVpositive hemodialysis patients in Europe was 29 new cases per thousand patients/year [271. In the United States, a nationwide survey of hemodialysis centers performed in 1991 by the Health Care Financing Administration in conjunction with the Centers for Disease Control and Prevention reported the percentage of NANBH to be 0.5% [28] . The prevalence of anti-HCV patients in selected hemodialysis units in the United States ranges from 15% to 25% [29, 30] . Also, in a multicenter prospective study including 499 patients from 11 hemodialysis units from different geographic regions in the United States, anti-HCV was detected in 10% of the patients, but the prevalence ranged widely (2% to 26%) [31] . Over the past few years, it has become clear that the vast majority (73% to 98%) of ELISA-2, ELISA-3, and/or RIBA-2-or -3positive hemodialysis patients are viremic [32] [33] [34] [35] [36] [37] and that the viremia persists [37] . This finding implies that most anti-HCVpositive hemodialysis patients awaiting transplantation are viremic. It also has become clear that anti-HCV antibodies develop long after the occurrence of viremia [38] . In two recent reports, hepatitis C virus RNA was detectable in the serum of 9% to 13% of anti-HCV-negative patients [39, 40] . It is therefore likely that some viremic but anti-HCV-negative hemodialysis patients undergo transplantation. Moreover, Oesterreicher et a! recently reported that in hemodialysis patients without anti-HCV or HCV RNA in the serum, HCV RNA can be detected in peripheral blood mononuclear cells [41] . Blood transfusions [29, 30, 33-35, 42, 43] , duration of hemodialysis [31, 32, 34, 35, [44] [45] [46] [47] , and intravenous drug abuse [29, 30, 33] have been incriminated as major risk factors for acquisition of HCV infection by patients undergoing hemodialysis. Although several studies have shown a highly significant association between the number of blood transfusions and the prevalence of anti-HCV among hemodialysis patients [29, 30, 33-35, 42, 43] , other studies failed to establish such a relationship and showed that duration of hemodialysis is the major risk factor for acquisition of HCV infection [31, 32, [44] [45] [46] [47] . Furthermore, antibodies to HCV can be detected in a substantial proportion (7% to 27%) of non-transfused hemodialysis patients [31, 42, 48] . The prevalence of anti-HCV is much lower among continuous ambulatory peritoneal dialysis (CAPD) patients (0% to 10%) compared with hemodialysis patients [49] [50] [51] [52] [53] . Recently, a large epidemiologic study in Spain (81 centers, 4684 patients) showed that, apart from the modality of dialytic treatment (hemodialysis versus chronic ambulatory peritoneal dialysis), the location of hemodialysis also greatly influences the prevalence of anti-HCV-positive patients (hospital hemodialysis, 34.8%; satellite hemodialysis, 25.4%; home hemodialysis, 6.8%) [531. These data indicate that, at present, we lack knowledge about several factors (intradialytic, intercenter, environmental, nosocomial, etc.) that might contribute to the transmission of HCV in the dialysis setting. Until these factors are elucidated, the application of effective preventive measures does not seem feasible.
Transmission of HCV infection via organ transplantation
Transplantation of organs from HCV-infected donors is another source of HCV infection in renal transplant recipients [54] [55] [56] [57] [58] [59] [60] [61] [62] . Policies regarding utilization of organs from anti-HCVpositive donors vary considerably among centers. For example, in the United States, a survey of 147 transplant centers showed that 54% of the centers do not utilize kidneys from anti-HCV-positive donors, 24% transplant such kidneys into anti-HCV-positive recipients only, 5% transplant these kidneys irrespective of the anti-HCV status of the recipient, and 17% of the centers do not have a specific policy [63] .
Prevalence of HCV infection among cadaver donors. The prevalence of HCV infection among cadaver donors varies widely among different centers. Recently, in a national collaborative study of 3078 cadaver organ donors from eight organ procurement organizations in the United States, the prevalence of ELISA-1, ELISA-2, and hepatitis C virus RNA-positive donors was 5.1%, 4.2%, and 2.4%, with a range from 1.5% to 16.7%, 2.3% to 8.3%, and 0.8% to 4.2%, respectively [54] . In another study, of the 484 cadaver donors screened, 89 (18%) were identified as ELISA-1 positive, of whom only 33 (6.8%) were also RIBA positive [55, 601. These inconsistencies have been attributed to differences in the geographic prevalence of HCV infection [54, 55, 641 . Roth et al found that the majority of anti-HCV-positive organ donors harbor active HCV infection, since in their study, liver tissue from 24 RIBA-positive donors showed chronic active hepatitis in 16 (67%), chronic persistent hepatitis in 2 (8%), and normal liver in 6 (25%) [55, 60] . Hepatitis C virus RNA was present in the serum of 88% (14/16) of the donors with chronic active or persistent hepatitis and in none of those with normal liver tissue [55] . Male gender, history of alcohol abuse, history of drug abuse, blood alcohol levels greater than 100 mg/dl, presence of potentially abused drugs in the blood, and detection of anti-HBc or anticytomegalovirus antibodies are important risk factors for the presence of anti-HCV in the serum of organ donors [54] . Organ donors with an absence of hepatitis-B-positive serology, normal liver function tests, and no history of drug abuse or homosexuality have been characterized as low-risk donors [56, 57] . However, the United States collaborative study provided strong evidence against the existence of "low-risk" donors, as no differences were found in the clinical and biochemical characteristics between ELISA-2-positive donors with and without detectable hepatitis C virus RNA in the serum [54] . Incidence of HCV transmission via organ transplantation. In the United States national collaborative study, a comparison drawn between recipients of organs from ELISA-2-positive donors with and without hepatitis C virus RNA (47 and 23 recipients, respectively) showed that, post transplantation, the prevalence of viremia and ELISA-2 seropositivity was significantly higher in recipients of organs from ELISA-2-positive/HCV-RNA-positive donors than in recipients of organs from ELISA-2-positive/HCV-RNA-negative donors (100% versus 43%, P < 0.001 for HCV RNA, and 73% versus 25%, P = 0.01 for ELISA-2) [54] . In the same study, a significantly higher (P = 0.04) prevalence of post-transplantation liver disease (defined as an increase in serum ALT to more than 2.5 times the upper limit of normal) was observed in recipients of organs from ELISA-2-positive/HCV-RNA-positive donors (22/47, 47%) than in recipients of organs from ELISA-2 positive/HCV-RNA negative donors (5/23, 22%). No significant differences were observed in the incidence of death and graft loss.
A striking feature regarding the incidence of transmission of hepatitis C virus via organ transplantation is the major differences among centers. In one of the earlier studies by Pereira et at, among 26 recipients of organs from 11 anti-HCV-positive donors (of whom 9 were HCV-RNA positive), the prevalence of HCV-RNA-positive recipients increased significantly after transplantation (7/26, 27% versus 23/24, 96%; P < 0.001) [58] . Moreover, all patients who were HCV-RNA negative before transplantation (13/13), and for whom post-transplantation serum samples were available, tested positive for HCV RNA after receiving an organ from an HCV-positive donor. In a more recent controlled study, Pereira and colleagues compared the outcome of 29 patients who received organs from 13 anti-HCV-positive donors with that of 74 patients who received organs from 37 donors who were randomly selected from a pool of 703 anti-HCV-negative donors [59] . Post transplantation, among recipients of organs from anti-HCVpositive donors, 67% (16/24) were ELISA-2 positive, and 96% (23/24) were HCV-RNA positive, whereas among organ recipients from anti-HCV-negative donors, only 20% (9/45) were ELISA-2 positive, and only 18% (8/44) were HCV-RNA positive (P < 0.001). In the same study, the prevalence of post-transplantation liver disease was higher in recipients of organs from anti-HCV-positive donors than in recipients of organs from anti-HCV-negative donors (16/29, 55% versus 11/69, 16%; P < 0.001). The risk of post-transplantation liver disease was 4.4-fold higher in recipients of organs from anti-HCV-positive donors. No differences were observed in the incidence and causes of death or graft loss, but the post-transplantation followup period was short (median followup, 42 months and 49 months, respectively). Other investigators have observed a much lower incidence of transmission of HCV infection by organ transplantation than did Pereira and coworkers [54, 58, [62] . The same study reported that although the incidence of hepatitis (defined as an elevation of ALT 100 units for more than 14 days) was higher in recipients of organs from HCV-RNApositive donors (38%) than in recipients of organs from HCV-RNA-negative donors (22%), this difference did not reach statistical significance. Further, neither fulminant hepatitis nor rapid progression to cirrhosis was observed. However, this study too had a short followup period (average, 612 days; range, 62 to 1154 days). In another study, none of 6 recipients of a kidney from an HCV-RNA-positive donor had detectable hepatitis C virus RNA in the serum 36 to 40 months after transplantation [63] . Roth has offered some hypotheses regarding the differences in the incidence of hepatitis C virus transmission via organ transplantation [64] , but definite explanations are not yet available. One factor that cannot be ignored as a possible explanation, however, is the method used for organ preservation. The rate of transmission of hepatitis C virus via organ transplantation has been much higher in centers using slush preservation [58] than in centers using pulsatile perfusion [55, 60, 62, 651 . Zucker and colleagues studied the effect of standard pulsatile renal preservation, and variations of it, on the number of viral copies in kidneys procured from HCV-infected donors [66] . Standard pulsatile perfusion eliminated 75% of the virus in 20 hours. Modification of this procedure by the inclusion of a second pulsatile perfusion eliminated more than 99% of the virus from the kidney. The same study reported that adding a high-flow-rate ultrafilter with a molecular cut-off of 300,000 daltons in series to the apparatus eliminated the virus from the perfusion solution in less than 2 hours. Thus it is likely that modifications in organ preservation techniques could reduce the incidence of transmission of hepatitis C virus by organ transplantation. It is clear that larger studies of this issue are needed.
Transplantation of organs from HCV-infected donors into HCVinfected recipients. In a number of centers, kidneys from anti-HCV-positive donors are transplanted into recipients who are known to be anti-HCV positive prior to transplantation. A prospective Spanish multicenter study discerned no significant differences between 24 ELISA-2-positive recipients of kidneys from ELISA-2-positive donors (followup, 26 8 months) and 40 ELISA-2-positive recipients of kidneys from ELISA-2-negative donors (followup, 30 10 months) in a variety of parameters: the prevalence of mild liver abnormalities (21% versus 33%), chronic liver disease (8% versus 8%), presence of serum HCV RNA (96% versus 77%), patient survival (100% versus 98%), and graft survival (96% versus 93%) [67] . Although the results of this study are encouraging, they should be interpreted with caution because:
(1) animal [681 as well as clinical [691 studies have shown that previous infection with hepatitis C virus protects neither from reinfection with a different strain of the virus, or even the same strain, nor from reappearance of liver disease. (2) The followup period of the study was short. Therefore, any adverse effects might not have manifested themselves yet, although, after an extension of the followup to 40 9 months and 49 11 months [70] , no significant differences were seen. 
Liver disease after renal transplantation
Liver disease, one of the most important complications of renal transplantation, significantly contributes to morbidity and mortality [72-761. Liver disease is defined as acute when abnormal liver function tests revert to normal within six months of disease onset, and as chronic when liver function abnormalities persist for longer than six months [75] . The reported prevalence of liver disease in renal transplant patients varies from 4% to 38% [75] . In a survey of 2041 patients reported in the literature, Rao and Anderson found the mean prevalence to be 16%; more recently, of 915 consecutive patients who underwent renal transplantation between 1971 and 1990 at their own institution, 180 (20%) and 119 (13%), respectively, were classified as having acute and chronic also can induce acute liver disease [75] . Acute forms of liver disease usually remit as the viral infection is cleared or the offending drug is discontinued [75] . In contrast, studies from different countries have shown that hepatic failure due to chronic liver disease is the cause of death in 21% [77] and 25% to 27% [78] [79] [80] of renal transplant recipients with functioning grafts for longer than five and ten years, respectively. In the past, most cases of chronic liver disease in renal transplant patients were attributed to hepatitis B virus infection, NANBH, hemosiderosis, or alcohol abuse. However, over the past few years, as a consequence of the dramatic reduction in the incidence of hepatitis B virus infection in patients undergoing hemodialysis and renal transplantation, as well as the discovery of hepatitis C virus and its identification as the major cause of NANBH, hepatitis C virus infection has emerged as the main cause of chronic liver disease in the renal transplant patient population.
HCV infection in renal transplant recipients
Most HCV-infected renal transplant recipients become infected before transplantation while they are on dialysis, but hepatitis C virus also can be acquired at the time of transplantation due to exposure to blood transfusions or organs from infected donors.
Prevalence of anti-HCJ/ and HCV RNA. The prevalence of anti-HCV-positive renal transplant recipients varies among centers. Using an ELISA-2 assay, we found 26% (4 1/156) of our renal transplant recipients to be anti-HCV positive [81] . This percentage is compatible with other studies in which 10% to 26% of transplant recipients were ELISA-2, anti-HCV positive ( Table 1 ) [82] [83] [84] [85] [86] [87] . The prevalence of anti-HCV-positive patients is influenced by various factors such as race [88] and geographic origin of the recipient [86] , mode of dialytic treatment (hemodialysis versus chronic ambulatory peritoneal dialysis) [82, 86] and duration of hemodialysis before transplantation [81, 84, 86, 89, 90] , number of blood transfusions [82, 84, 89] , number of previous transplants [89, 90] , and the presence of hepatitis B virus infection [86, 89] . The majority (74% to 95%) of ELISA-2-positive renal transplant recipients are viremic (HCV RNA is present in the serum) ( Table   Table 2 [82, 83, 85, 87, 91] , and the viremic state persists in almost all patients [39, 82, 92] .
Implications of HCV infection. Biochemical evidence of liver disease has been reported in 20% to 70% of ELISA-2-and/or RIBA-2-and/or HCV-RNA-positive renal transplant recipients [81, 82, 84, 86, 87, 90] . Furthermore These findings indicate that a considerable number of HCVinfected renal transplant patients maintain normal liver function test results and, in some studies, such patients are classified as not having liver disease. These data, however, should be interpreted with caution, as liver function tests and liver histology are poorly correlated. We recently found that 7 of 27 ELISA-2-positive recipients with abnormal liver function tests (26%) had an essentially normal liver on histologic examination, whereas 6 of 10 patients with normal liver function tests (60%) had chronic liver disease [91] . Our findings correspond with those of others [75, 86, 93, 94] . We also found that serum hepatitis C virus RNA is a poor predictor of liver histology: it was detected in 9 of 10 patients (90%) with no significant changes, 3 of 3 patients with acute hepatitis, and 22 of 24 patients (92%) with various histologic forms of chronic liver disease [91] . We also observed no relationship between the number of viral copies present in the serum and liver histology (unpublished data). Today's cases are an example of this. Patient 2, who had histologic evidence of severe liver disease and cirrhosis, had much lower levels of viremia compared to Patient 1, who had only very mild liver disease. A "healthy" carrier state (HCV-RNA-positive, normal liver function test results, normal liver histology) also has been reported in 8% to 10% of HCV-infected renal transplant recipients [91, 95] . Thus, data show that in HCV-infected patients, neither anti-HCV nor liver function tests, viremia, or degree of viremia predict the presence or severity of liver disease. Liver biopsy is therefore essential for diagnostic, prognostic and, possibly, therapeutic purposes. We have adopted this policy in our unit. In the absence of any contraindications, renal transplant recipients with evidence of hepatitis C virus infection undergo liver biopsy regardless of the results of their liver function tests. Renal [86, 91, 93, 96] . In contrast, when liver biopsies are performed only in patients with liver functional abnormalities, more severe lesions predominate [83, 84] . For example, in the studies by Morales et al [98] and Roth et al [83] , in which all patients who underwent liver biopsy had long-standing biochemical evidence of chronic liver disease, the prevalence of cirrhosis was 23% (7/30) and 20% (2/10), respectively. On the other hand, in our study in which liver biopsy was done irrespective of liver functional abnormalities, the prevalence of cirrhosis was only 4% (3/68) [96] . Another factor that should be considered in the evaluation of the histologic data in HCV-infected renal transplant recipients is the timing of the liver biopsy. In all histopathologic studies, liver biopsy was performed within a relatively short period after transplantation, between one and 144 months (Table 4 ). Early biopsy could account for the relatively high prevalence of mild histologic forms of liver disease observed, as it is known that in patients with hepatitis C virus infection, severe hepatic lesions such as cirrhosis can take as long as 20 or 30 years to develop. This view is supported by the findings of Hestin and coworkers, who noted that post-transplantation time was significantly longer in 16 transplant recipients with a Knodell index of greater than 5 (chronic hepatitis) than in 14 patients with a Knodell index of less than 5 (58 56 months versus 35 29 months, P < 0.001) [85] . The relatively high prevalence of cirrhosis reported by Morales et al possibly could be explained by the fact that more than one-half of their patients had biochemical evidence of chronic liver disease before transplantalion [84, 98] . That is, the time interval between onset of liver disease and liver biopsy might have been relatively long.
Another explanation for the wide variation in the severity of hepatic lesions might be infection with different hepatitis C virus genotypes [99] . For example, in the French and Italian general population with hepatitis C, genotype lb/Il is the most prevalent and is more frequently associated with cirrhosis than are other genotypes [99] . Note that Patient 2, who developed severe liver Berthoux, 1995 [861 43 Numerals in brackets refer to reference numbers b KI, Knodell index disease, was infected with this genotype (ib). Of our 68 patients, only two liver biopsies (3%) revealed advanced fibrosing cholestatic hepatitis; in two other patients (3%), the biopsy specimen revealed an early stage of this lesion [96] . These four patients had the heaviest viral load compared with patients in the other histologic groups, although the differences were not statistically significant (unpublished data). To date, this aggressive form of liver disease was thought to occur only from recurrent hepatitis B in patients receiving liver grafts [100, 101] . Recently, however, fibrosing cholestatic hepatitis has been described in two hepatitis B virus-infected renal transplant recipients [102, 103] and in one heart transplant recipient with donor organ-transmitted hepatitis C virus infection [104] .
Clinical and biochemical studies suggest that the course of chronic liver disease in a substantial proportion of HCV-infected renal transplant patients is not progressive. But histologic data, which are more reliable, indicate that the course of liver disease is characterized by progressive fibrosis. Liver disease progressively worsened in 11 of 14 consecutive HCV-infected renal transplant recipients (79%) who underwent liver biopsies within 24 to 144 months (development of cirrhosis in three and deterioration of the Knodell index in eight) [84] . We recently studied the course of liver disease in 15 HCV-infected renal transplant recipients whose initial biopsy showed chronic hepatitis (13 patients), early fibrosing cholestatic hepatitis (one patient), or minimal hepatitis (one patient) [96] . Followup biopsies were performed 17.1 4.9 months after the initial biopsy. Despite the short interval between biopsies, the extent of fibrosis (stage) increased significantly in the infection has a long natural history. Large, long-term, comparative histopathologic studies, supplemented with detailed virologic data, are needed to define precisely the course of liver disease in hepatitis C virus-infected renal transplant recipients. Some data indicate that the course of liver disease is more aggressive when hepatitis C virus infection is acquired at the time of transplantation, rather than before or after [71] .
The critical question, however, is not whether there is hepatic disease, but whether hepatitis C virus infection alters patient outcome. Several studies have shown that hepatitis C virus infection does not affect survival of renal transplant recipients [39, 83, 84, 86, 88, 89, 94, 97, 98, 105, 106] . Recently, however, Pereira and colleagues reported a significantly higher mortality rate (9/22, 41% versus 12/78, 15%; P = 0.009) and a 3.3-fold increased risk of death after renal transplantation in patients who were anti-HCV positive prior to transplantation, compared with patients who were anti-HCV negative before transplantation [90] . The causes of death also were significantly different (P = 0.02) between the two groups. Sepsis was the major cause of death in patients who were anti-HCV positive prior to transplantation; these patients had a 9.9-fold increased risk of dying from sepsis after transplantation [90] . This study contrasts with other investigations, which have shown that anti-HCV neither affects patient survival nor is associated with an increased incidence of death due to sepsis or liver failure [39, 83, 84, 86, 88, 89, 94, 97, 98, 105, 106] . Pereira et al have proposed possible explanations for this discrepancy: differences between the studies regarding the prevalence and severity of the liver disease before transplantation, differences in the virulence between strains of the virus, and differences in "completeness" of the studies. These investigators posed the critical question: should anti-HCV-positive dialysis patients undergo transplantation or continue dialysis? Apart from patient survival, the other major concern in renal transplantation is graft survival. Pouteil-Noble et al found that the incidence of acute rejection episodes was significantly higher in anti-HCV-positive than in anti-HCV-negative renal transplant recipients (33/78, 87% versus 101/136, 74%; P < 0.004) [105]. Similarly, Roth and coworkers found the percentage of RIBApositive patients who experienced acute rejection episodes to be nearly twice that of RIBA-negative patients (40/109, 37% versus 41/200, 20%; P < 0.002) [83] . But several other studies have shown no significant differences in the incidence of acute rejection episodes between HCV-infected and non-infected renal transplant recipients [88, 90, 94, 106] . In addition, recipients who were anti-HCV positive prior to transplantation tended to have fewer rejection episodes than did recipients who were anti-HCV negative prior to transplantation [90] . In search of an explanation for the increased incidence of rejection episodes in their patients, Roth and colleagues suggested two possibilities: (1) that the causative factor was the markedly reduced amount of immunosuppressive therapy received by their patients following a serious infection (42% of their RIBA-positive patients with infection had at least one rejection episode), and (2) that, analogous to the association of cytomegalovirus infection and rejection, hepatitis C virus infection upregulates MHC class-Il antigens in the allograft [83] . Corell et al observed a significantly lower incidence of acute rejection episodes in anti-HCV-positive compared with anti-HCV-negative renal transplant recipients (28% versus 40%; P 0.025), even though a significantly higher proportion of immunologically high-risk patients belonged to the anti-HCV-positive group (30.5% versus 11.8%; P = 0.00003) [107] . This lower incidence was attributed to the relative reduction of CD4 CD5RA (naïve T-helper) cells in anti-HCV-positive patients, a reduction associated with altered T-cell proliferative responses to different mitogens.
Chronic hepatitis C virus infection is associated not only with hepatic lesions, but with a variety of immunologically mediated extrahepatic conditions as well, particularly mixed cryoglobulinemia and glomerulonephritis (GN) [108] . Hepatitis C virus is the major cause of essential mixed cryoglobulinemia; anti-HCV and HCV RNA are detectable in the serum of more than 80% of patients with this condition [108] . Although membranoproliferative glomerulonephritis (MPGN) is the most common form of GN observed in HCV-infected patients, other forms such as membranous, acute proliferative, and sclerosing ON have been reported [109] . Does de-novo HCV-related GN develop in HCV-infected renal allograft recipients? Epidemiologic data indicate such a possibility. Membranous nephropathy occurred more frequently in anti-HCV-positive than in anti-HCV-negative renal transplant recipients (6/141, 4% versus 2/455, 0.44%; P < 0.02) [110] . Berthoux's review of all graft biopsies performed on 399 renal transplant recipients revealed 12 cases of membranous GN and 9 cases of MPGN [86] . The prevalence of hepatitis C virus infection was 25% (3/12) in patients with membranous ON and 78% (7/9) in patients with MPGN. Compared to the prevalence of HCV infection in the entire renal transplant group (117/399, 29%), the prevalence of HCV infection was significantly different only for MPGN (P = 0.001). Moreover, a ninefold increase in the prevalence of MPGN was observed among HCV-infected, compared with non-HCV-infected, recipients (7/117, 6% versus 2/282, 0.7%). Recent non-epidemiologic data support the potential association between HCV infection and MPGN in renal transplant recipients. Roth and colleagues described five HCV-infected noncryoglobulinemic renal transplant recipients with proteinuria due to MPGN; in none of these patients was MPGN or a known immune-complex disease the cause of the original nephropathy [111] . Comparison of the physicochemical properties of the HCV virions between these patients and five HCV-infected, nonproteinurie renal transplant patients provided indirect evidence that immune complexes consisting of HCV antigen and anti-HCV antibody are present in the circulation of HCV-infected recipients with MPGN.
Hepatocellular carcinoma (HCC), another serious complication of HCV infection, is observed more frequently in some parts of the world. In Japan, for example, where HCC is one of the most common forms of cancer, mortality rates show a constant and significant increase [112] . In the general (worldwide) population, HCC occurs more frequently in patients with chronic hepatitis C than in patients with chronic hepatitis B, and HCC can develop in non-cirrhotic patients with chronic hepatitis C [113, 114] . Data regarding the development of HCC in HCV-infected renal transplant recipients are lacking, probably because of the short followup period of the studies; it is known that HCC is a late complication of HCV infection. Noteworthy is that non-Hodgkins' lymphoma recently was diagnosed in 14 non-transplant patients with chronic hepatitis C [115] . In all 14, anti-HCV and HCV RNA were present in the serum, and HCV RNA was present in peripheral blood mononuclear cells.
Some data have become available regarding patients who are co-infected with the hepatitis B and hepatitis C viruses. Huang et a! compared 28 anti-HCV-positive/HBsAg-positive and 51 anti-HCV-positive/HBsAg-negative renal transplant recipients [1161. No differences appeared in the prevalence of deaths related to liver disease, but chronic hepatitis and cirrhosis occurred more frequently in the co-infected patients than in patients who were anti-HCV positive only (50% versus 25.5%; P = 0.026 for chronic hepatitis, and 21% versus 0%; P = 0.001 for cirrhosis). Recently, Pouteil-Noble and colleagues studied 235 renal transplant recipients, of whom 189 were HCV infected and 46 were co-infected with the HCV and HBV at the time of transplantation [87] .
Following transplantation, biochemical evidence of chronic hepatitis was present in 50% of the HCV-infected and in 64% of the co-infected recipients. Although patient survival did not differ between the two groups, hepatic failure was observed more frequently among the HCV/HBV co-infected patients (7/41, 17% versus 12/156, 7%). Furthermore, liver biopsy in 108 patients (81 HCV infected and 27 HCV/HBV co-infected) showed that the incidence of minimal-change lesions was higher in HCV-infected (13/81, 16%) than in HCV/HBV co-infected (2/27, 7.5%) patients [871. In contrast, the incidence of cirrhosis was higher in HCV/ HBV co-infected patients (7/27, 26%) than in patients who were infected only with hepatitis C(8/81, 10%) [87] . These data suggest that, in HCV-infected renal transplant recipients, co-infection with HBV is associated with more aggressive liver disease.
How should we manage the renal transplant recipient with HCV infection? We have some information about two possible approaches: reduction of immunosuppression and treatment with interferon alpha (INF-a). Hepatitis C virus RNA titers rise after transplantation in HCV-infected renal transplant recipients. An association between immunosuppression and number of serum HCV RNA titers also has been found [117] . Therefore, reduction of immunosuppression might benefit the patient by decreasing the degree of viremia. Reducing immunosuppression should be considered carefully, however, because this approach has been related to acute rejection [83] . Nevertheless, since there are no firm data regarding the harmfulness of specific immunosuppressive drugs, we tend to concentrate on the net state of the patient's immunosuppression. Therefore, in our department, all the HCVinfected renal transplant recipients receive reduced doses of immunosuppressive drugs without exclusion of any specific drug.
Interferon alpha, apart from having antiviral properties, is immunostimulatory as well. It can increase the expression of HLA antigens by the cells, induce cytokine gene expression, and enhance the effector function of cytotoxic T-lymphocytes, natural killer cells, and macrophages [71, . These properties might explain the high incidence of acute, irreversible vascular rejection observed approximately 10 years ago in renal transplant recipients receiving INF-a prophylactically for cytomegalovirus infection [121, 122] . Thervet et al conducted a pilot study in which 13 renal transplant recipients with biopsy proven chronic hepatitis received r-INF-a for a mean of 4.5 (one to 11) months [123] . Clinical tolerance was poor (treatment had to be withdrawn in more than one-half of the patients) and, although liver enzyme activities were reduced during treatment, they returned to pretreatment levels after therapy ended. Furthermore, 2 of 12 patients developed acute deterioration of graft function. Rostaing and colleagues prospectively studied 16 renal transplant recipients with chronic hepatitis C and stable renal function for at least one year (serum creatinine, 1.4 0.5 mg/dl), who were scheduled to receive r-INF-a (3 MU 3 times/week for 6 months) [124] . Fifteen of the patients were HCV RNA positive at the beginning of the study. During treatment, ALT levels returned to normal in 15 of the patients (94%), but 7 of the responders (47%) relapsed one to 9 weeks after discontinuation of treatment. One month after treatment, HCV RNA was present in the serum of all patients who were viremic before therapy started. In this study as well, tolerance to the drug was poor; 4 patients (25%) dropped out of the study because of side effects. A worrying finding in this study was the significant increase in serum creatinine levels observed during INF-a treatment (162.5 57.6 versus 125.4 41 jtmol/ liter; P < 0.05), with renal failure developing in 6 of the patients (38%). Two of these six responded to methylprednisolone antirejection treatment with improved graft function; renal failure progressed in the remaining four. Graft biopsy in patients with deterioration of renal function during INF-a treatment revealed various lesions, including acute tubular necrosis with interstitial hemorrhage in one patient, chronic rejection in another, and interstitial edema with scattered mononuclear cell infiltration and mesangial hypertrophy in others [123, 124] . None of the patients had the lesions of acute cellular or vascular rejection that had been described in earlier studies [121, 122] . It is therefore possible that INF-a causes deterioration of graft function in renal transplant recipients not only by inducing acute rejection but also through other mechanisms. Such mechanisms could include direct nephrotoxicity, induction of cytokines, and acute interstitial nephritis [123, 124] . Current data thus suggest that INF-a therapy can be potentially dangerous in HCV-infected renal transplant recipients.
Reduction of immunosuppression is a possible, albeit a seriously flawed, approach to therapy in the HCV-infected renal transplant recipient. But I believe that using interferon alpha is untenable given the current evidence. I agree with Thervet et a!:
"The use of INF-cs is likely to be avoided in this specific indication" [123] , and with Rostaing and colleagues: "We do not recommend using INF-n for chronic hepatitis C in renal transplant recipients" [124] . In our unit we are very reluctant to treat HCV-infected renal transplant recipients with INF-cs. Perhaps other, newer antiviral agents such as ribavirin will prove safer. To the best of my knowledge, there are no published data regarding the use of these agents in renal transplant recipients. So the answer to the question of what can be done therapeutically for renal transplant recipients with HCV infection is, very little if anything at all.
Can anything be done to help these patients while they are undergoing dialysis and awaiting transplantation? I don't know. Recent clinical and clinicopathologic studies have shown that in HCV-infected hemodialysis patients, INF-a treatment is well tolerated and its efficacy is comparable to that observed in the general population [125-1 27], but reappearance of viremia occurs frequently [127] . Pol et a! noted a discrepancy among biochemical, histologic, and virologic parameters in a study of 19 HCV-infected hemodialysis patients who underwent treatment with r-INF-a (3 MU three times/week for 6 months) [127] . Of the 12 patients (75%) who underwent liver biopsy before and after treatment, 9 showed improvement or normalization of the hepatic lesions. Of 13 patients with abnormal liver tests, 11(85%) responded with normalization of the tests, and 73% of the responders (8/fl) were long-term responders. However, of 15 patients who were HCV-RNA positive prior to treatment, 7 (47%) were HCV-RNA positive at the end of treatment, and 12 (80%) were HCV-RNA positive at the end of the followup period [127] . Let me repeat: frequent reappearance of viremia after INF-a treatment is a serious problem. This especially applies to patients undergoing lNF-treatment while they are renal transplant candidates, because when the time for transplantation and initiation of immunosuppressive therapy arrives, the majority of these patients will still be viremic. Perhaps HCV-infected dialysis patients require more prolonged treatment with INF-a. Poynard et al recently suggested just that for patients with NANB hepatitis [1281. Factors that one should consider in assessing the potential response to INF-cs are quantity of viremia and hepatitis C virus genotypes. Furthermore, neutralizing and binding interferon antibodies were detected in the serum of HCV-infected patients who, despite having an initial response, experienced relapse during treatment with recombinant INF-n (breakthrough) [129] . In light of all these data, we should not draw definite conclusions regarding the efficacy and safety of INF-a therapy in HCVinfected dialysis patients until the results of large, prospective controlled studies comparing different INF-a treatment regimens are available. These studies will have to include detailed analyses of the clinical, histologic, virologic, and immunologic parameters of the patients before and after treatment. The title of that editorial still applies today. But an ancient Chinese proverb says that before one can reach a destination one thousand miles away, one must take the first step. I think we have taken that first step with hepatitis C, and I feel certain that soon the thousand-mile destination will be reached.
QUESTIONS AND ANSWERS

DR. NlcoLAos E. MADIAS (Chief Division of Nephrology, New
England Medical Center, Boston, Massachusetts): You referred to rapid-sequence variation of the hype rvariable region of HCV and formation of escape variants. Does the rate of formation of such variants increase with INF-a or immunosuppressive therapy? DR. V0sNIDEs: The limited data on this issue are based on a small number of patients. In a study from England, sequence nucleotide changes of the hypervariable region located in the E2/NSI protein of the HCV genome occurred more commonly in two untreated than in two IFN-a-treated patients with chronic hepatitis C [131] . In a Japanese study, multiple sequence variations of the hypervariable part of the E2/NS1 region were frequent in three patients with chronic hepatitis C who did not respond to INF-p therapy, but the variations were not observed in three responders [132] . In a more recent French study of patients with serologic evidence of active HCV infection receiving INF-13 therapy, the nucleotide sequence variation of the El region of the HCV genome was low, regardless of the response to treatment [133] . In contrast, an increased degree of sequence variation was have been documented in patients with chronic hepatitis C from the general population [9, 137] as well as in hemophiliacs [138] . The prevalence of mixed infections with HCV of different types also is higher among patients who have acute exacerbations of chronic hepatitis C than among those who do not [137] . Mixed infections with HCV of different genotypes also occur in hemodialysis patients [125] and in renal transplant recipients [136, 139] .
DR. MADIAs: Are data available on comparable anti-HCVpositive patients who were either maintained on hemodialysis or who received transplants that will allow us to judge the impact of transplantation on the natural course of HCV-associated hepatic disease? DR. V05NIDE5: I am not aware of any controlled studies comparing the course of liver disease in HCV-infected dialysis patients with that of HCV-infected renal transplant recipients. Controlling for a number of baseline factors, we found that patients with anti-HCV at the time of referral had a higher risk of death. The higher relative risk of death in the anti-HCVpositive patients did not differ significantly among patients who received a transplant or those who remained on dialysis. These findings suggest that HCV infection adversely affects survival in end-stage renal disease irrespective of mode of therapy, but that transplantation does not adversely affect survival rates in patients with HCV infection. Although this study does not substitute for a randomized controlled trial, we think it is the best information we can present so far. We conclude that anti-HCV-positive status alone is not a contraindication for renal transplantation. We recommend that anti-HCV-positive patients with end-stage renal disease be allowed to make an informed choice between dialysis and transplantation. DR. JOHN T. HARRINGTON (Dean, Tufts University School of Medicine, Boston, Massachusetts): You mentioned that Zucker and associates reduced the hepatitis C transmission to zero when they utilized a filter in their pulsatile perfusion system [66] . Are you using such a system? Should we all be using such a system? DR. VOSNIDES: No, we use slush preservation. But it is possible that the size of the viral inoculum plays an important role in the transmission of HCV infection and the induction of HCV-related liver disease. Zucker et al used refined molecular biology techniques and found that (1) the kidney is not a site of HCV replication, and (2) modifications of the standard pulsatile perfusion technique completely eliminated the virus from the HCVinfected kidneys [661. It is thus possible that with these preservation techniques, the viral burden of the procured kidneys from HCV-infected donors, and consequently the viral inoculum, is reduced or completely eliminated, and that the risk of transmission of HCV decreases significantly or even possibly disappears. If future studies prove that the technique reported by Zucker et al eliminates the risk of transmission of HCV from infected donor kidneys, then yes, I think all of us should be using such a preservation system. DR. MADIAS: How would you manage the anti-HCV patient on hemodialysis who wishes to receive a renal transplant? DR. VosNmEs: This is a one million dollar-or 247 million drachmas-question. Our decisions rely mostly on liver histopathology and the presence of viremia. As a general rule, we do not offer transplants to patients with high degrees of necroinflammatory activity or fibrosis on liver biopsy. Our current policy could be summarized as follows: Serum HCV RNA is determined in all anti-HCV-positive dialysis patients regardless of liver function tests; the same applies for all anti-HCV-negative patients with persistently abnormal liver function tests. All anti-HCV-positive and/or HCV-RNA-positive patients undergo liver biopsy. With the exception of patients whose liver biopsy shows advanced cirrhosis, all viremic patients receive treatment with INF-a, 3 million units 3 times weekly for one year. In fact, we are contemplating extension of the treatment to 18 months, and we also are considering the possibility of treating our patients with a combination of INF-a and ribavirin. If the initial biopsy shows mild lesions (low grade and low stage), we probably would avoid performing a second liver biopsy. Otherwise, a second liver biopsy is performed when the INF-s therapy is completed. If significant improvement or normalization of the histologic lesions is seen on the second biopsy specimen, and the patient becomes free of viremia, renal transplantation is offered, although ideally we should wait another six months and determine whether the patient remains free of viremia. I must admit that we have transplanted kidneys into a limited number of patients who have had mild hepatic lesions, even if they were viremic. Yet we are puzzled about whether we are doing the right thing. In some of these patients, post-transplantation followup liver biopsies showed no significant changes compared to the initial biopsy, while in other patients, the extent of fibrosis increased significantly. Nevertheless, the necroinfiammatory lesions remained the same or even decreased slightly. I know that our policy sounds strict. However, we have seen quite a few renal transplant recipients with HCVrelated hepatic disease that caused considerable morbidity, in some cases, cirrhosis and even death from liver failure usually associated with infection. Another factor that strongly affects our decisions is the serious shortage of donor organs in Greece. We do a lot of living-related renal transplantations. As a matter of fact, last year more than 50% of renal transplantations performed in this country were from living-related donors. In the setting of transplantation from living donors, you have to make the best of it, and preparation of the recipient should be meticulous, even "ideal."
In their recent study from the New England Organ Bank, Pereira et al demonstrated that pre-transplantation HCV infection is associated with an increased risk of liver disease and death after transplantation [901. These results made us skeptical of whether anti-HCV-positive patients on dialysis should be offered renal transplantation as opposed to continuing dialysis. We are currently trying to find out whether a relationship between the severity of the initial liver histopathologic lesions, histopathologic course of liver disease, and HCV genotypes exists. This information probably will give us some guidelines as to whether in some patients, for example those infected with the genotype ib, a strict transplantation policy should be applied, whereas in other patients, for example those infected with genotype 2 or 3, a more liberal policy could be adopted. DR. MADIAS: Dr. Levey, could you describe to us your views on this issue? DR. LEVEY: 1 agree that patients with anti-HCV and evidence of liver disease (persistently or intermittently elevated serum transaminase level) should have a liver biopsy prior to renal transplantation. Liver biopsy is the best method for assessing the prognosis of liver disease after transplantation. This information is important, because if the biopsy reveals an advanced degree of liver damage, either according to the necrosis index or the fibrosis, the outcome after renal transplantation is likely to be poor, and I think it is very important that the patient knows that. It is also true that the outcome of dialysis also is likely to be poor, and the patient deserves to know this as well. I am intrigued by the idea of treating these patients with interferon prior to transplantation, but until the long-term results of this approach are known, I am not ready to make as sweeping a recommendation as you have. As you know, most patients with anti-HCV do indeed have viremia.
Based on the response of non-immunosuppressed patients to interferon therapy, I suspect that the number of patients who would be rendered free of viremia is probably relatively small, and immunosuppression might reactivate HCV infection. So I differ with you, Gregory, on this: I wouldn't prohibit anti-HCV-positive patients from making their own choice whether to have a renal transplant if the biopsy showed only mild liver disease. We don't have studies demonstrating that their long-term prognosis is worse than if they did not receive a transplant. In fact, our recent study suggests that we can't tell them that the prognosis is worse [1401. Although I am concerned that it might he worse, my own concern should not prevent them from having a renal transplant if their quality of life on dialysis is poor.
DR. VosNiDes: You recently found that viremia increases
tremendously after transplantation and initiation of immunosuppression [88] . You found that the median increase in posttransplantation HCV RNA titer was 6.6-fold and that the increase ranged from 1.8-to 30.3-fold.
DR. LEVEY: Yes, these patients are at risk for viremia, but our study suggests that the increase in risk of death is not significantly different whether they remain on dialysis or receive a transplant.
DR. DEMETRIOS VLAHAKOS (Onassis Cardiac Surgery Center,
Athens): You mentioned that hepatitis C does not adversely affect graft survival and that death from hepatic complications in HCV-infected patients occurs in the late post-transplant period, years after transplantation. Since transplantation is a cost-effective method that offers the best quality of life in patients with end-stage renal disease, could we not transplant organs from HCV-positive donors to recipients with co-morbid conditions who are expected to live less than two or three years on hemodialysis? DR. V0SNwES: I am not aware of any formal studies addressing this issue. Organs (heart, liver, and lung) from HCV-infected donors have been used for life-saving transplants. I should clarify that all the data I cited refer to the course and outcome of hepatic disease in HCV-infected dialysis patients undergoing renal transplantation. Regarding the dialysis patients who acquire HCV infection at the time of transplantation, for example, by receiving a kidney from an HCV-infected donor, the course of the liver disease is probably different. Some evidence suggests that the course of liver disease in such patients is more aggressive than in those who acquire the infection prior to transplantation, while they are on dialysis [69, 86, 1041 . We have had the same experience, albeit in a small number of patients. Perhaps hepatic disease is more virulent in renal transplant recipients who acquire HCV infection at the time of transplantation because they develop acute hepatitis while receiving maximum immunosuppression. So, although your suggestion is not unreasonable, I am worried that by adopting such a policy, another morbid condition, that is, liver disease, will he added to patients who already have other serious co-morbid conditions and, therefore, death could occur sooner than expected had they not acquired HCV infection. DR. VLAHAK0S: The ELISA-2 can recognize more epitopes on the HCV antigen and thus is a more sensitive test. Does this imply that the ELISA-2 is less specific?
DR. V05NIDEs: The ELISA-2 test for detecting anti-HCV antibody is both more sensitive and more specific than the ELISA-1 test [10, 15, 16] [142] . Furthermore, the bDNA technique has disclosed a significant correlation between serum and liver viral load [143] . Using RT-PCR, a recent French study detected HCV RNA in the livers of 29 of 30 (97%) renal transplant recipients with detectable HCV RNA in the serum [83] . DR. MADIAs: Is any information available about treating HCV infection with INF-f3? DR. V05NIDE5: I am aware of three studies, all from Japan [144] [145] [146] . In the first study, a prospective controlled trial including 25 patients with acute non-A, non-B hepatitis, 11 of the patients were treated with INF-for an average of 30 days, and 14 acted as controls (no treatment) [144] . Four patients in the treatment group still had raised ALT levels after one year followup and therefore were given a second course of INF-13. Followup at three years revealed that 10 of the ii treated patients, but only 3 of the 14 controls, had normal serum ALT levels. Serum HCV RNA was undetectable in 10 of the 11 treated patients and in only 1 of the 12 controls. In the second study, INF-p was given to 97 consecutive patients with acute non-A, non-B hepatitis who were randomly allocated to six different dose regimens [145] . The total dose of INF-p ranged between 8.4 million and 336 million units. Seventy-four patients were anti-HCV positive (ELISA-2); of these, 65 were HCV-RNA positive. Ninety patients (74 with hepatitis C and 16 with non-hepatitis C) were analyzed at the end of the trial. Biochemical resolution, that is, normalization of the ALT level, was observed in 15 of the 16 (94%) patients with non-hepatitis C (anti-HCV negative/HCV-RNA negative). In contrast, only 28 of 74 (38%) anti-HCVpositive patients showed biochemical resolution. Then the rate of biochemical resolution was determined in the six different treatment groups. Among anti-HCV-positive patients, only the patients who received the highest total dose (336 million units) showed a high resolution rate (10 of 12, 83%); in the other five groups (lower total dose of INF), the resolution rate ranged between 0% and 38%. Similarly, among the 65 HCV-RNApositive patients, sustained disappearance of viremia was observed in 90% (9 of 10) of those receiving the highest dose (total dose, 336 million units) and in 0% to 46% of the patients receiving the lower dose (total dose, 8.4 million to 168 million units). Also, biochemical resolution of acute hepatitis C was accomplished even in patients with high levels of viremia, provided sufficiently large doses of INF-/3 were given. The third study, using detection, typing, and quantification of serum HCV, comprised 50 randomly selected patients with chronic hepatitis C [146] . Of the 50, 24 responded to INF-f3 therapy with sustained normalization of ALT (complete responders), and 26 did not respond (nonresponders). The pretreatment levels of viremia were significantly lower in complete responders than in nonresponders, whereas genotypes did not seem to influence the response to INF-13 therapy. General Hospital): We use the new classification of chronic hepatitis for the interpretation of liver biopsies [1] . The new classification, which has been widely accepted by hepatologists internationally, is based on two parameters: (1) hepatitis activity or grade, defined by the necroinflammatory changes such as piecemeal necrosis, portal inflammation, and focal or confluent necrosis of the parenchyma, and (2) stage of the disease, defined by the extent of fibrosis. The stage is actually the result of the activity and is related to the time course of hepatitis. The peculiarity in our group of patients is the low hepatitis activity compared to that of hepatitis C in the general population. In addition, our patients develop fibrosis in a rather short time.
Higher-stage fibrosis develops in our patients in about two years, but in the general population, the time interval for disease progression is approximately nine years. Although stage increases significantly, grade slightly decreases. A similar observation has been made in liver transplant patients. In this group of immunosuppressed patients, histologic changes are more severe in the early post-transplant period [148] . One can assume that the improvement of histology in later stages accounts for disease activity and not for hepatitis stage. DR. V0sNIDEs: Nor do I have data for this region. I do know that in France, although the incidence of idiopathic membranoproliferative glomerulonephritis is declining [150] , HCV infection is common.
DR. BOLETIS: A 1993
French study found no relationship between HCV infection and membranoproliferative glomerulonephritis [151] . Nor did the Italian multicenter study [152, 153] . In only one American [154] and one Japanese [155] study was a relationship between HCV infection and membranoproliferative glomerulonephritis found. I think this issue is controversial. DR. HADJICONSTANTJNOU: I would like to return to the question of the current incidence of hepatitis C in the so-called developed world, including the hemodialysis population. It appears that hepatitis B continues to be a major problem in hemodialysis units, even in the Western world. We would expect that the situation is improving, owing to the testing of blood and blood products before transfusion, a substantial decrease in the need for blood transfusions in the erythropoietin era, and the widespread vaccination of all hemodialysis patients against hepatitis B. However, I was surprised by a communication in the U.S. Centers for Disease Control's Morbidity and Mortality Weekly Report about outbreaks of hepatitis B among hemodialysis patients in California, Nebraska, and Texas in 1994 [156] . Amazingly, most of the patients had not been vaccinated against hepatitis B, although the vaccine has been commercially available for the past 15 years. So what can we expect for hepatitis C, for which no vaccine is yet available? DR. LEVEY: Hepatitis B vaccine is sometimes not used routinely in hemodialysis patients in the U.S. because the prevalence of HBV infection in this group is low, the efficacy of the vaccine in stimulating antibody production is not high, and other infection control measures generally are sufficient to prevent the spread of infection. However, in hemodialysis populations with a high prevalence of HCV infection, HCV appears to be transmitted in the dialysis unit [157] , and I suspect an effective vaccination would be widely used. DR [126] . Subsequently, 303 patients were randomly allocated to receive the same treatment for an additional 12 months (group 1, 103 patients), a regimen of one million units three times/week for 12 months (group 2, 101 patients), or no further treatment (group 3, 99 patients). At 18 months, a significantly higher proportion of patients in group 1 (45%) had normal serum ALT values as compared with those in group 2 (27%) and group 3 (30%). Similarily, between 19 and 42 months, a significantly higher proportion of patients in group 1 (22%) continued to have normal serum ALT as compared with those in group 2 (10%) and group 3 (8%). Furthermore, among 176 patients with repeated liver biopsies at 18 months, significantly more patients in group 1 (70%) had improved histologic activity scores than in group 2 (48%) or group 3 (39%). So it seems that for patients with chronic non-A, non-B hepatitis, a regimen of 3 million units of TNF-a given 3 times/week for 18 months is more beneficial than lower doses or a shorter duration of treatment. [163] , and rhabdomyolysis [164] . Regarding the second part of your question, I don't know what accounts for the differences between renal transplant and nontransplant patients. DR. B0LETIs: You mentioned that less immunosuppression could benefit the course of the liver disease. Should we avoid any specific immunosuppressive drugs in HCV-infected renal transplant recipients? DR. VOSNIDES: Although we have no firm data, Morales et al reported that the clinical course of HCV-infected renal transplant recipients with chronic liver disease who were receiving cyclosporme A was better than that of renal transplant recipients receiving azathioprine [82, 104] . Hestin and colleagues noted that among renal transplant recipients with histologic evidence of chronic hepatitis C, those with a Knodell's index of greater than 5 were more frequently treated with azathioprine than those with a Knodell's index of less than 5 [83] . Furthermore, Roth and coworkers used logistic regression analysis to show that in RIBApositive renal transplant recipients, anti-lymphocyte globulin treatment was a predictor of abnormal liver function [81] . DR. V05NIDEs: There are no controlled data, but I think that in non-immunosuppressed patients, hepatitis C has a more benign course than in immunosuppressed patients. A large long-term study compared the mortality rate of 568 subjects with posttransfusion non-A, non-B hepatitis, who were identified in five major prospective studies performed between 1967 and 1980, with the mortality rate of control subjects who had received blood transfusions but who did not have hepatitis [165] . Each study patient was matched with two control subjects (first control group and second control group). After an average followup of 18 years, the mortality rate from all causes did not differ significantly among the three groups (51%, 50%, and 52% for the hepatitis patients, the first, and the second control group, respectively). Mortality due to liver disease was slightly but significantly higher in the patients with hepatitis (3.3%, 1.1%, and 2% for the patients, the first, and the second control groups, respectively). Of the deaths related to liver disease, 71% occurred in patients with chronic alcoholism. This study contrasts sharply with that of Pereira et al, who, as I said earlier, reported a 3.3-fold higher mortality rate and a 9.9-fold higher incidence of death due to sepsis after renal transplantation in recipients who were anti-HCV-positive compared with those who were anti-HCV-negative prior to transplan-tatiOn [901. Furthermore, the increased risk of death in anti-HCVpositive recipients was apparent within a relatively short period after transplantation (median followup, 45 months). So it seems that in immunosuppressed patients, hepatitis-C-related liver disease is more aggressive than in non-immunosuppressed patients. DR. LEVEY: I agree. Previous studies on immunosuppression in patients with chronic hepatitis B infection also disclosed that the patients treated with prednisone did worse than those who did not receive immunosuppression [1661.
DR. MADIAS: Dr. Levey, would you comment on the occurrence of sepsis in patients with graft-related HCV liver disease? Was the incidence of cytomegalovirus disease increased in these patients?
DR. LEVEY: Our study comparing hepatitis-C-positive versus hepatitis-C-negative transplant recipients identified an increased risk of death from sepsis in patients with hepatic disease [901.
Earlier work comparing the course of hepatitis-B-positive versus hepatitis-B-negative patients after renal transplantation produced the same finding [167] . What is the basis for the apparent increased risk of infectious complications in renal transplant patients with liver disease? I don't know. Clearly, the risk of infection in patients with cirrhosis-independent of renal transplant or the immunocompromised status-is increased, and this might account for the finding. Regarding your second question, we did not identify CMV infection as the cause of sepsis in the patients we saw.
If I may make one other comment in response to Dr. Harrington's question. He asked specifically about data correlating liver histology with fatal outcome in renal transplant recipients with hepatitis C. I am not aware of such data, hut there are very good data from 20 years ago correlating the extent of hepatic pathologic changes and death from liver disease in patients with hepatitis B but without renal disease [1681. There is no reason to think that that relationship would be different in renal transplant patients. I think these older data very strongly direct us to make our prognosis from the results of liver biopsies. That is, the liver biopsy stands up as a better marker of the severity of liver disease than does the serum biochemical evidence.
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